Immunotherapy-Chemo cocktail shows promise in tough breast cancer
NCT ID NCT03213041
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried other treatments. The goal was to see if the combo could slow cancer growth or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) combined with carboplatin chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-negative metastatic breast cancer that has not responded to prior therapies.
What could go wrong
This is a very small, early-phase trial with only 12 participants and no placebo group. The results may not apply to all patients, and the combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States